{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:48:48Z","timestamp":1789174128802,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","award":["not appicable"],"award-info":[{"award-number":["not appicable"]}],"id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40263-024-01109-9","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:02:09Z","timestamp":1722679329000},"page":"733-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct05267405","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-4038","authenticated-orcid":false,"given":"Yaroslav","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Abou Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Pati\u00f1o Tob\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Fuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"6","key":"1109_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2023.0066","volume":"80","author":"A Schulze-Bonhage","year":"2023","unstructured":"Schulze-Bonhage A, Hirsch M, Knake S, Kaufmann E, Kegele J, Rademacher M, et al. Focal cortex stimulation with a novel implantable device and antiseizure outcomes in 2 prospective multicenter single-arm trials. JAMA Neurol. 2023;80(6):588\u201396.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1109_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069\u201377.","journal-title":"Epilepsia"},{"issue":"9","key":"1109_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935\u201363.","journal-title":"CNS Drugs"},{"issue":"855","key":"1109_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"15","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;15(855):175\u201382.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"1109_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","volume":"37","author":"E Perucca","year":"2023","unstructured":"Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755\u201379.","journal-title":"CNS Drugs"},{"issue":"9","key":"1109_CR6","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.17007","volume":"62","author":"JA French","year":"2021","unstructured":"French JA, Chung SS, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142\u201350.","journal-title":"Epilepsia"},{"issue":"10","key":"1109_CR7","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398.","journal-title":"Neurology"},{"issue":"6","key":"1109_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"key":"1109_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"\u00c1 Beltr\u00e1n-Corbellini","year":"2023","unstructured":"Beltr\u00e1n-Corbellini \u00c1, Romeral-Jim\u00e9nez M, Mayo P, S\u00e1nchez-Miranda Rom\u00e1n I, Iruzubieta P, Chico-Garc\u00eda JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71\u20137.","journal-title":"Seizure."},{"issue":"3","key":"1109_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, G\u00f3mez-Ib\u00e1\u00f1ez A, Garc\u00e9s M, Serrano-Castro P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918\u201329.","journal-title":"Epilepsia Open."},{"issue":"2","key":"1109_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","volume":"38","author":"PJ Serrano-Castro","year":"2024","unstructured":"Serrano-Castro PJ, Ram\u00edrez-Garc\u00eda T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38(2):141\u201351.","journal-title":"CNS Drugs"},{"issue":"4","key":"1109_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522\u201330.","journal-title":"Epilepsia"},{"key":"1109_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107306","volume":"200","author":"S Aboumatar","year":"2024","unstructured":"Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, et al. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200: 107306.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1109_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.seizure.2007.01.004","volume":"16","author":"S Chung","year":"2007","unstructured":"Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16(4):296\u2013304.","journal-title":"Seizure."},{"issue":"10","key":"1109_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(04)00882-8","volume":"3","author":"E Beghi","year":"2004","unstructured":"Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3(10):618\u201321.","journal-title":"Lancet Neurol"},{"issue":"Pt A","key":"1109_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106574","volume":"101","author":"F Weissinger","year":"2019","unstructured":"Weissinger F, Losch F, Winter Y, Brecht S, Lendemans D, Kockelmann E. Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: results from a German prospective multicenter clinical practice study. Epilepsy Behav. 2019;101(Pt A): 106574.","journal-title":"Epilepsy Behav"},{"key":"1109_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108429","volume":"126","author":"M Privitera","year":"2022","unstructured":"Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022;126: 108429.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1109_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17134","volume":"63","author":"JW Sander","year":"2022","unstructured":"Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139\u201349.","journal-title":"Epilepsia"},{"issue":"11","key":"1109_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40263-017-0480-6","volume":"31","author":"CS Kwok","year":"2017","unstructured":"Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of \u201cthird-generation\u201d antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959\u201374.","journal-title":"CNS Drugs"},{"key":"1109_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yebeh.2016.03.005","volume":"59","author":"SS Chung","year":"2016","unstructured":"Chung SS, Hogan RE, Blatt I, Lawson PB, Nguyen H, Clark AM, et al. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Epilepsy Behav. 2016;59:13\u201320.","journal-title":"Epilepsy Behav"},{"issue":"12","key":"1109_CR21","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1212\/WNL.56.12.1772","volume":"56","author":"K Krakow","year":"2001","unstructured":"Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56(12):1772\u20134.","journal-title":"Neurology"},{"issue":"1","key":"1109_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"issue":"22","key":"1109_CR23","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"issue":"10","key":"1109_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075\u201388.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1109_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5698\/1535-7511.17.3.180","volume":"17","author":"C Harden","year":"2017","unstructured":"Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17(3):180\u20137.","journal-title":"Epilepsy Curr."},{"issue":"4","key":"1109_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.yebeh.2007.12.019","volume":"12","author":"HM de Boer","year":"2008","unstructured":"de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540\u20136.","journal-title":"Epilepsy Behav"},{"issue":"Pt 11","key":"1109_CR27","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/brain\/awh267","volume":"127","author":"A Gaitatzis","year":"2004","unstructured":"Gaitatzis A, Johnson AL, Chadwick DW, Shorvon SD, Sander JW. Life expectancy in people with newly diagnosed epilepsy. Brain. 2004;127(Pt 11):2427\u201332.","journal-title":"Brain"},{"key":"1109_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.yebeh.2017.12.037","volume":"80","author":"Y Winter","year":"2018","unstructured":"Winter Y, Daneshkhah N, Galland N, Kotulla I, Kr\u00fcger A, Groppa S. Health-related quality of life in patients with poststroke epilepsy. Epilepsy Behav. 2018;80:303\u20136.","journal-title":"Epilepsy Behav"},{"key":"1109_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2022.07.003","volume":"100","author":"Y Winter","year":"2022","unstructured":"Winter Y, Uphaus T, Sandner K, Klimpe S, Stuckrad-Barre SV, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. Seizure. 2022;100:109\u201314.","journal-title":"Seizure."},{"issue":"3","key":"1109_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/epi.16819","volume":"62","author":"N Sinha","year":"2021","unstructured":"Sinha N, Peternell N, Schroeder GM, de Tisi J, Vos SB, Winston GP, et al. Focal to bilateral tonic-clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy. Epilepsia. 2021;62(3):729\u201341.","journal-title":"Epilepsia"},{"issue":"11","key":"1109_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/jnnp-2017-316211","volume":"88","author":"GS Bell","year":"2017","unstructured":"Bell GS, de Tisi J, Gonzalez-Fraile JC, Peacock JL, McEvoy AW, Harkness WFJ, et al. Factors affecting seizure outcome after epilepsy surgery: an observational series. J Neurol Neurosurg Psychiatry. 2017;88(11):933\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1109_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.107014","volume":"186","author":"S Aboumatar","year":"2022","unstructured":"Aboumatar S, Biton V, Wechsler R, Ferrari L, Rosenfeld WE. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. Epilepsy Res. 2022;186: 107014.","journal-title":"Epilepsy Res"},{"key":"1109_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1109_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1109_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/epi.16832","volume":"62","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596\u2013614.","journal-title":"Epilepsia"},{"issue":"7","key":"1109_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","volume":"48","author":"G Zaccara","year":"2007","unstructured":"Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223\u201344.","journal-title":"Epilepsia"},{"issue":"6","key":"1109_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318.","journal-title":"CNS Drugs"},{"key":"1109_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2015.07.008","volume":"138","author":"XQ Wang","year":"2015","unstructured":"Wang XQ, Lv B, Wang HF, Zhang X, Yu SY, Huang XS, et al. Lamotrigine induced DIHS\/DRESS: manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;138:1\u20137.","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"1109_CR39","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1007\/s00415-023-11825-9","volume":"270","author":"Y Winter","year":"2023","unstructured":"Winter Y, Sandner K, Glaser M, Ciolac D, Sauer V, Ziebart A, et al. Synergistic effects of vagus nerve stimulation and antiseizure medication. J Neurol. 2023;270(10):4978\u201384.","journal-title":"J Neurol"},{"issue":"2","key":"1109_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/epd2.20004","volume":"25","author":"Y Winter","year":"2023","unstructured":"Winter Y, Sandner K, Vieth T, Groppa S. Eslicarbazepine acetate for the treatment of status epilepticus. Epileptic Disord. 2023;25(2):142\u20139.","journal-title":"Epileptic Disord"},{"issue":"8","key":"1109_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40263-022-00937-x","volume":"36","author":"M S\u00e1enz-Farret","year":"2022","unstructured":"S\u00e1enz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Antiseizure drugs and movement disorders. CNS Drugs. 2022;36(8):859\u201376.","journal-title":"CNS Drugs"},{"issue":"10","key":"1109_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40263-022-00954-w","volume":"36","author":"Y Winter","year":"2022","unstructured":"Winter Y, Sandner K, Vieth TL, Melzer N, Klimpe S, Meuth SG, et al. Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults: a prospective observational study. CNS Drugs. 2022;36(10):1113\u20139.","journal-title":"CNS Drugs"},{"issue":"9","key":"1109_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","volume":"16","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16(9):82.","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01109-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T16:05:32Z","timestamp":1723305932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01109-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"14 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Y.W. received an unrestricted grant from Angelini Pharma for medical writing assistance and statistical work. Angelini Pharma was not involved in the study design; the collection, analysis, and interpretation of the data gathered; nor the writing of the study report or the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y.W. reports honoraria for educational presentations and consultations from Axsome Therapeutics, Bayer AG, BIAL, Eisai, LivaNova, Novartis, and UCB Pharma. S.F. received honoraria for educational presentations and consultations from Eisai. S.G. received compensation for professional services from Abbott, Abbvie, Bial, Medtronic, UCB, and Zambon; and research grants from Abbott, Boston Scientific, MagVenture, German Research Council, and German Ministry of Education and Health. R.A.D. and S.P.T. declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the local ethics committee of the state medical association Rheinland-Pfalz (No: 837.560.17).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients signed informed consent for participation in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Y.W. conceptualized the study and carried out the methodology, validation, formal analysis, investigation, resources, data curation, writing\u2014review and editing, visualization, and supervision; R.A.D. conceptualized the study and performed project administration, validation, investigation, resources, writing\u2014original draft, and writing\u2014review and editing; S.P.T. performed project administration, data curation, and writing\u2014review and editing; S.G. carried out visualization, and writing\u2014review & editing; S.F. conceptualized the study and carried out writing\u2014review and editing, supervision, and project administration. All authors have read and approve the final manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}